Another important aspect of PD-1+Tim-3+ is that it provides a new perspective in immunotherapy (for the design of targeted therapies) and tumor progression, establishing the response to the interaction between cancer and immune cells, and guiding prognosis in patients. The gene discussed is HAVCR2; the disease is neoplasm.